Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report

Table 5 Comparison of efficacy of the two treatment options groups

Treatment options	Cases	ORR%	CR/n CR%
Bortezomib-containing regimens	39	94.9	61.51
Thalidomide-containing regimens	22	86.4	18.2
P value		P > 0.05	P = 0.001

Comparison of bortezomib-containing regimens and thalidomide-containing regimens treatment options. There were significant difference (P = 0.001) in CR/nCR and no significant difference in ORR

ISSN: 1477-7819